Dyclonine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)

Targets (1)Biointeractions (1)

Identification

Name

Dyclonine

Accession Number

DB00645 (APRD00940)

Type

Small Molecule

Groups

Approved

Description

Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone

2-(1-Piperidyl)ethyl P-butoxyphenyl ketone

3-Piperidino-4'-butoxypropiophenone

4-Butoxy-beta-piperidinopropiophenone

4-N-Butoxy-beta-(1-piperidyl)propiophenone

4'-Butoxy-3-piperidinopropiophenone

Diclonina

Dyclocaine

Dyclonin

Dyclonine

Dycloninum

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Dyclonine hydrochloride	ZEC193879Q	536-43-6	KNZADIMHVBBPOA-UHFFFAOYSA-N	Details

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Cepacol Sore Throat Spray	Spray	0.1 %	Oral	Reckitt Benckiser	1999-07-01	2012-03-23	Canada
Periorinse	Rinse	.1 g/100mL	Dental; Oral; Topical; Transmucosal	Centura Pharmaceuticals, Inc	2016-06-16	Not applicable	US
Sore Throat Relief	Lozenge	3 mg	Oral	Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.	Not applicable	Not applicable	Canada
Sucrets Black Cherry	Lozenge	3 mg/1	Oral	Insight Pharmaceuticals	2009-06-18	Not applicable	US
Sucrets Childrens Cherry	Lozenge	1.2 mg/1	Oral	Insight Pharmaceuticals	2009-07-28	Not applicable	US
Sucrets Extra Strength Mint Flav.loz 3mg	Lozenge	3 mg	Oral	Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.	1994-12-31	1998-08-25	Canada
Sucrets for Kids	Lozenge	1.2 mg	Oral	Insight Pharmaceuticals	1997-08-15	Not applicable	Canada
Sucrets for Kids	Lozenge	1.2 mg	Oral	Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.	1992-12-31	1998-08-25	Canada
Sucrets Ms Wintergreen	Lozenge	3 mg/1	Oral	Insight Pharmaceuticals	2009-07-28	Not applicable	US
Sucrets Regular Strength Lemon Flav.loz 2mg	Lozenge	2 mg	Oral	Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.	1994-12-31	1998-08-25	Canada
Sucrets Regular Strength Lemon Flavoured Lozenges	Lozenge	2 mg	Oral	Heritage Brands, A Subsidiary Of Insight Pharmaceuticals Llc	1997-08-15	2009-06-19	Canada
Sucrets Sore Throat	Lozenge	3 mg	Oral	Insight Pharmaceuticals	2007-05-31	Not applicable	Canada
Sucrets Sore Throat Spray 0.1% Cherry	Aerosol	.1 %	Oral	Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.	1993-12-31	1996-09-12	Canada
Sucrets Wild Cherry	Lozenge	2 mg/1	Oral	Insight Pharmaceuticals	2009-07-28	Not applicable	US

Unapproved/Other Products

Not Available

International Brands

Name	Company
Dyclone	AstraZeneca
Sucrets	Insight Pharmaceuticals

Brand mixtures

Name	Labeller	Ingredients
Ambix First Aid	Organics Corporation Of America Dba Ambix Laboratories	Dyclonine Phenol
Benzethonium Chloride and Dyclonine Hydrochloride	Walgreen	Benzethonium Dyclonine
Benzethonium Chloride Plus Dyclonine Hydrochloride	Cvs Health	Benzethonium Dyclonine
Cepacol Sore Throat	Reckitt Benckiser	Dyclonine Glycerin
Skin Shield	Insight Pharmaceuticals	Benzethonium Dyclonine
Skin Shield Liquid Bandage	Del Pharmaceuticals Inc.	Benzethonium Dyclonine Ethanol
Sucrets Complete	Insight Pharmaceuticals	Dyclonine Menthol
Sucrets Complete Cool Citrus	Insight Pharmaceuticals	Dyclonine Menthol
Sucrets Complete Sore Throat, Cough and Irritation	Insight Pharmaceuticals	Dyclonine Menthol Pectin
Sucrets Complete Vapor Cherry	Insight Pharmaceuticals	Dyclonine Menthol
Tanac Medicated Gel	Del Pharmaceuticals Inc.	Allantoin Dyclonine

Categories

UNII

078A24Q30O

CAS number

586-60-7

Weight

Average: 289.4125
Monoisotopic: 289.204179113

Chemical Formula

C₁₈H₂₇NO₂

InChI Key

BZEWSEKUUPWQDQ-UHFFFAOYSA-N

InChI

InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3

IUPAC Name

1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one

SMILES

CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1

Pharmacology

Indication

Used to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.

Structured Indications

Pharmacodynamics

Dyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.

Mechanism of action

Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Sodium channel protein type 10 subunit alpha	Protein	yes	inhibitor	Human	Q9Y5Y9	details

Absorption

Readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Approximately 30 to 60 minutes.

Clearance

Not Available

Toxicity

Symptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole.	Experimental
Acepromazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Dyclonine is combined with adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine.	Approved, Investigational
Alfaxalone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Dyclonine is combined with Alfentanil.	Approved, Illicit
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Alphacetylmethadol.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.	Approved, Illicit, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Dyclonine is combined with Amitriptyline.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Dyclonine is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide.	Experimental
Aripiprazole	The risk or severity of adverse effects can be increased when Dyclonine is combined with Aripiprazole.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Asenapine.	Approved
Azelastine	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Azelastine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Dyclonine is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.	Illicit
Benzocaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzocaine.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Dyclonine is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Bromazepam.	Approved, Illicit
Brompheniramine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Brotizolam.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine.	Approved, Investigational
Buprenorphine	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Dyclonine is combined with Butalbital.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.	Approved, Illicit, Vet Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Dyclonine is combined with Carfentanil.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Carisoprodol.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlormezanone.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine.	Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorphenamine.	Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorzoxazone.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine.	Approved, Vet Approved
Citalopram	The risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Dyclonine is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Clobazam.	Approved, Illicit
Clomipramine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.	Approved, Illicit
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine.	Approved, Illicit
Cyclizine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclobenzaprine.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyproheptadine.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dantrolene.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine.	Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Dyclonine is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Dyclonine is combined with Desflurane.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine.	Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dezocine.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Diazepam.	Approved, Illicit, Vet Approved
Difenoxin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydrocodeine.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.	Experimental, Illicit
Dimenhydrinate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenhydramine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenoxylate.	Approved, Illicit
Doxepin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Doxepin.	Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ecgonine.	Experimental, Illicit
ECGONINE METHYL ESTER	The risk or severity of adverse effects can be increased when Dyclonine is combined with ECGONINE METHYL ESTER.	Experimental
Efavirenz	The risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz.	Approved, Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Dyclonine.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Entacapone.	Approved, Investigational
Escitalopram	The risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Estazolam.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine.	Approved
Ethanol	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fexofenadine.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Flibanserin.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Flurazepam.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.	Approved
Fluticasone Propionate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dyclonine.	Approved, Investigational
Fosphenytoin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol.	Approved, Illicit
Gabapentin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Dyclonine is combined with gabapentin enacarbil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Dyclonine is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit
Glutethimide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Glutethimide.	Approved, Illicit
Guanfacine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.	Approved
Halothane	The risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Heroin.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital.	Approved
Hyaluronidase	The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine.	Approved, Investigational
Hydrocodone	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Iloperidone.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.	Investigational, Withdrawn
Isoflurane	The risk or severity of adverse effects can be increased when Dyclonine is combined with Isoflurane.	Approved, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Lamotrigine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levobupivacaine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Levorphanol.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine.	Approved, Vet Approved
Lithium	The risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Dyclonine is combined with Lofentanil.	Illicit
Loratadine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Lurasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved, Vet Approved
Maprotiline	The risk or severity of adverse effects can be increased when Dyclonine is combined with Maprotiline.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Meclizine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Melperone.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine.	Approved
Methotrimeprazine	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Methsuximide.	Approved
Methylphenobarbital	The risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital.	Approved
Metyrosine	Dyclonine may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved, Investigational
Mirtazapine	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Molindone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved, Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Nalbuphine.	Approved
Nefazodone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Nefazodone.	Approved, Withdrawn
Nitrazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrazepam.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrous oxide.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Dyclonine is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Dyclonine is combined with Nortriptyline.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Dyclonine is combined with Opium.	Approved, Illicit
Orphenadrine	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.	Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxazepam.	Approved
Oxprenolol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Paliperidone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Paliperidone.	Approved
Paraldehyde	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Pentazocine.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine.	Approved
Phenobarbital	The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenobarbital.	Approved
Phenytoin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Pimozide.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Pipotiazine.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide.	Approved
Pramipexole	Dyclonine may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam.	Approved, Illicit
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Dyclonine.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Prilocaine.	Approved
Primidone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Promethazine.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Propoxycaine.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Quazepam.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Quetiapine.	Approved
Ramelteon	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ramelteon.	Approved, Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Dyclonine is combined with Remifentanil.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Risperidone.	Approved, Investigational
Ropinirole	Dyclonine may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine.	Approved
Rotigotine	Dyclonine may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Dyclonine.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.	Approved, Vet Approved
Sertindole	The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Dyclonine is combined with Sevoflurane.	Approved, Vet Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.	Approved
Suvorexant	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tasimelteon.	Approved
Technetium Tc-99m tilmanocept	Dyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin.	Investigational
Thalidomide	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Thioridazine.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Dyclonine is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride.	Approved, Investigational
Tizanidine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tizanidine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tolcapone.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Dyclonine is combined with Topiramate.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Dyclonine is combined with Triazolam.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluoperazine.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Triprolidine.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Dyclonine.	Approved, Investigational
Venlafaxine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Dyclonine is combined with Vigabatrin.	Approved
Vortioxetine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine.	Approved
Zaleplon	The risk or severity of adverse effects can be increased when Dyclonine is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.	Approved
Zolpidem	Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Dyclonine is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Dyclonine is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Dyclonine is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen, "Oral Preparation of Dyclonine Hydrochloride." U.S. Patent US20080200506, issued August 21, 2008.

US20080200506

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14783
KEGG Compound	C07881
PubChem Compound	3180
PubChem Substance	46506697
ChemSpider	3068
ChEBI	4724
ChEMBL	CHEMBL1201217
Therapeutic Targets Database	DAP000509
PharmGKB	PA164748037
Drug Product Database	5669
Drugs.com	http://www.drugs.com/cdi/dyclonine-lozenges.html
Wikipedia	Dyclonine

ATC Codes

N01BX02

R02AD04

AHFS Codes

52:16.00

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (73.4 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1, 2	Completed	Treatment	Gingival Inflammation	1

Pharmacoeconomics

Manufacturers

Astrazeneca lp

Packagers

Dosage forms

Form	Route	Strength
Cream	Topical
Liquid	Topical
Liquid	Oral
Spray	Oral	0.1 %
Rinse	Dental; Oral; Topical; Transmucosal	.1 g/100mL
Lozenge	Oral	3 mg/1
Lozenge	Oral	1.2 mg/1
Lozenge	Oral
Lozenge	Oral	1.2 mg
Lozenge	Oral	2 mg
Lozenge	Oral	3 mg
Aerosol	Oral	.1 %
Lozenge	Oral	2 mg/1
Gel	Topical

Prices

Unit description	Cost	Unit
Dyclonine hcl powder	4.9USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	174-175	Bockstahler, E.R.; U.S.Patent 2,771,391; November 20,1956; assigned to Allied Laboratories, Inc. Florestano, H.J., Jeffries, S.F., Osborne, C.E. and Bahler, M.E.; U.S. Patent 2,868,689; January 13, 1959; assigned to Allied Laboratories, Inc.
water solubility	Soluble (HCl salt)	Not Available
logP	3.7	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.046 mg/mL	ALOGPS
logP	4.11	ALOGPS
logP	3.68	ChemAxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	15.88	ChemAxon
pKa (Strongest Basic)	8.36	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	29.54 Å²	ChemAxon
Rotatable Bond Count	8	ChemAxon
Refractivity	87.07 m³·mol^-1	ChemAxon
Polarizability	35.14 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9856
Caco-2 permeable	+	0.7155
P-glycoprotein substrate	Substrate	0.7596
P-glycoprotein inhibitor I	Inhibitor	0.8077
P-glycoprotein inhibitor II	Non-inhibitor	0.6392
Renal organic cation transporter	Inhibitor	0.7801
CYP450 2C9 substrate	Non-substrate	0.8107
CYP450 2D6 substrate	Non-substrate	0.5142
CYP450 3A4 substrate	Substrate	0.5313
CYP450 1A2 substrate	Inhibitor	0.8914
CYP450 2C9 inhibitor	Inhibitor	0.793
CYP450 2D6 inhibitor	Inhibitor	0.8932
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.8574
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.5388
Ames test	Non AMES toxic	0.7961
Carcinogenicity	Non-carcinogens	0.8823
Biodegradation	Not ready biodegradable	0.7106
Rat acute toxicity	2.3661 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Strong inhibitor	0.8071
hERG inhibition (predictor II)	Inhibitor	0.6351

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organic oxygen compounds

Sub Class

Organooxygen compounds

Direct Parent

Alkyl-phenylketones

Alternative Parents

Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Piperidines / Beta-amino ketones / Trialkylamines / Azacyclic compounds / Organopnictogen compounds

Substituents

Alkyl-phenylketone / Phenoxy compound / Benzoyl / Phenol ether / Aryl alkyl ketone / Alkyl aryl ether / Monocyclic benzene moiety / Beta-aminoketone / Piperidine / Benzenoid

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

piperidines, aromatic ketone (CHEBI:4724 )

Targets

Details

1. Sodium channel protein type 10 subunit alpha

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Voltage-gated sodium channel activity
Specific Function:: Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:: SCN10A
Uniprot ID:: Q9Y5Y9
Molecular Weight:: 220623.605 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Roghani S, Duperon DF, Barcohana N: Evaluating the efficacy of commonly used topical anesthetics. Pediatr Dent. 1999 May-Jun;21(3):197-200. [PubMed:10355012 ]
Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974 ]

Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 15:40

Get DrugBank to go!

Structure for DB00645 (Dyclonine)

Targets

References